WILEX is a biopharmaceutical company and develops drugs based on antibodies
and small molecules with a low side effect profile and targeted treatment of
different types of cancer as well as diagnostic agents for specific detection
of tumours. WILEX’ aim is to help oncologists administer targeted treatments
to carefully diagnosed patients and to enhance patients' quality of life.
Latest News
15.02.2012: WILEX Inc. appoints Walter Carney as CSO for the further development
of Oncogene Science diagnostics. WILEX
Inc., a wholly owned US subsidiary of WILEX AG, today announced that Walter Carney, Ph.D., has joined the company as Chief Scientific Officer
(CSO)..... (More).
Seite gelesen: 350 | Heute: 8